BI-3231
Probe criteria
| Inhibitor/agonist potency: goal is < 100 nM (IC50, Kd) | hHSD17B13: Ki = 0.7 ± 0.2 nM (Enzymatic assay); DSF (temperature shift): 16.7 K in the presence of NAD+ |
| Selectivity within target family: > 30-fold | hHSD17B11: IC50 > 10 µM (enzymatic assay) |
| Selectivity outside target family | Eurofins Safety screen (44 targets) at 10 µM: clean except for PTGS2 (COX2) (49% ctrl)Clean PDSP scan (43 targets at 10 µM) |
| On target cell activity for cell-based targets: goal is < 1 µM IC50/EC50 | IC50 = 11 ± 5 nM (Cellular hHSD17B13 assay, HEK cells) |
| Control compound (100 times less potent than the probe) | BI-0955: Ki = > 10 µM (Enzymatic hHSD17B13 assay); IC50 > 10 µM (Cellular hHSD17B13 assay); Eurofins Safety screen (44 targets): PTGS2 (COX2) (44% ctrl), HTR2B (45 % ctrl)Clean PDSP scan (43 targets at 10 µM) |